Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis
- 27 April 2022
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 63, 103832
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
- Sanofi Genzyme
This publication has 29 references indexed in Scilit:
- Alemtuzumab and chronic plaque psoriasisBritish Journal of Dermatology, 2013
- Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasisJournal of Dermatological Science, 2013
- Psoriasis during natalizumab treatment for multiple sclerosisJournal of Neurology, 2012
- Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated CytolysisPLOS ONE, 2012
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- Psoriasis during interferon beta treatment for multiple sclerosisNeurological Sciences, 2009
- Quantitative signal detection using spontaneous ADR reportingPharmacoepidemiology and Drug Safety, 2009
- Review: Natalizumab in the treatment of multiple sclerosisTherapeutic Advances in Neurological Disorders, 2009
- Sphingosine-1-Phosphate Signaling and the SkinAmerican Journal of Clinical Dermatology, 2007
- Differential Expression of Activation Epitopes of β1 Integrins in Psoriasis and Normal SkinJournal of Investigative Dermatology, 1998